Jingrui Jiang

Author PubWeight™ 15.09^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.	Cancer Cell	2007	3.23
2	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.	Cancer Biol Ther	2007	2.12
3	Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.	Blood	2006	1.83
4	A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.	Mol Cell Proteomics	2009	1.25
5	Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.	Mol Cancer Ther	2007	1.18
6	Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.	Blood	2008	1.09
7	Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.	Gastroenterology	2006	1.09
8	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.	Blood	2008	1.01
9	Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.	Genes Cancer	2010	0.87
10	Discovery and characterization of novel mutant FLT3 kinase inhibitors.	Mol Cancer Ther	2010	0.84
11	Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27.	Clin Lymphoma Myeloma Leuk	2011	0.81